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Although	therapeutically	targeting	a	single	signaling	pathway	that	drives	tumor	development	and/or	progres-
sion	has	been	effective	for	a	number	of	cancers,	in	many	cases	this	approach	has	not	been	successful.	Target-
ing	networks	of	signaling	pathways,	instead	of	isolated	pathways,	may	overcome	this	problem,	which	is	prob-
ably	due	to	the	extreme	heterogeneity	of	human	tumors.	However,	the	possibility	that	such	networks	may	be	
spatially	arranged	in	specialized	subcellular	compartments	is	not	often	considered	in	pathway-oriented	drug	
discovery	and	may	influence	the	design	of	new	agents.	Hsp90	is	a	chaperone	protein	that	controls	the	folding	
of	proteins	in	multiple	signaling	networks	that	drive	tumor	development	and	progression.	Here,	we	report	
the	synthesis	and	properties	of	Gamitrinibs,	a	class	of	small	molecules	designed	to	selectively	target	Hsp90	in	
human	tumor	mitochondria.	Gamitrinibs	were	shown	to	accumulate	in	the	mitochondria	of	human	tumor	cell	
lines	and	to	inhibit	Hsp90	activity	by	acting	as	ATPase	antagonists.	Unlike	Hsp90	antagonists	not	targeted	to	
mitochondria,	Gamitrinibs	exhibited	a	“mitochondriotoxic”	mechanism	of	action,	causing	rapid	tumor	cell	
death	and	inhibiting	the	growth	of	xenografted	human	tumor	cell	lines	in	mice.	Importantly,	Gamitrinibs	were	
not	toxic	to	normal	cells	or	tissues	and	did	not	affect	Hsp90	homeostasis	in	cellular	compartments	other	than	
mitochondria.	Therefore,	combinatorial	drug	design,	whereby	inhibitors	of	signaling	networks	are	targeted	to	
specific	subcellular	compartments,	may	generate	effective	anticancer	drugs	with	novel	mechanisms	of	action.
Introduction
Backed by an unprecedented knowledge of cancer genes (1), it is 
now possible to disable signaling mechanisms of tumor cells with-
out affecting normal tissues using targeted therapy (2, 3). As pio-
neered by the development of a small molecule antagonist of the 
BCR-ABL kinase, i.e., imatinib mesylate, targeted cancer therapy is 
feasible (2), and has produced, in some cases, spectacular clinical 
responses (4). However, the underlying concept of target-centric 
drug discovery based on high-throughput screening of potential 
druggable molecules has been difficult to generalize. Costly, labor-
intensive, and low-yield (typically one in a million hits reaches the 
market) (5) target-centric drug discovery has generated many hope-
ful agents that provided minimal or no gains when tested in the 
clinic (6, 7). This high rate of failure may be due to the extreme het-
erogeneity of even seemingly identical tumors, carrying hundreds 
of mutated, amplified, or deregulated genes (8, 9). Such complex-
ity makes it difficult to identify a single, driving, signaling pathway 
suitable for therapeutic intervention, and raises concerns that an 
imatinib-like approach to drug discovery (4) may be feasible only 
in a handful of tumors (6).
To overcome these barriers, efforts have begun to explore systems 
biology tools (10) to model cancer pathways as globally intercon-
nected networks (11). Such connectivity maps, linking together 
multiple signaling pathways (12), may more faithfully recapitu-
late the tumor tactics responsible for treatment failure, including 
redundancy, buffering, and modularity into semiautonomous 
subnetworks (6). This information can also be exploited for a novel 
pathway-oriented drug discovery (11), with the goal of identifying 
inhibitors of nodal proteins (5), i.e., molecules that integrate mul-
tiple signaling subnetworks (6, 11). The expectation is that such 
network inhibitors may be best suited to simultaneously disable 
multiple mechanisms of tumor maintenance instead of a single 
gene and thus overcome the genetic and molecular heterogeneity 
of progressive disease. The molecular chaperone Hsp90 is a cancer 
nodal protein (13) and a potentially ideal candidate for pathway-
oriented drug discovery (14). In concert with other chaperones, 
Hsp90 oversees fundamental mechanisms of protein folding qual-
ity control via sequential ATPase cycles (15). A distinctive feature of 
this pathway is its compartmentalization in multiple, semiautono-
mous, subcellular networks. Accordingly, Hsp90-directed folding 
controls the stability of hosts of client proteins in the cytosol (15, 
16), disassembles transcriptional complexes in the nucleus (17), 
regulates the early secretory pathway in the endoplasmic reticu-
lum (18), and mediates cell motility in the extracellular milieu (19). 
Recent studies have expanded this paradigm to another subcellular 
compartment, the mitochondrion, in which Hsp90 and its related 
chaperone, TRAP-1 (20), bind components of a permeability tran-
sition pore, notably cyclophilin D (CypD) (21), and antagonize its 
opening, preserving organelle integrity and suppressing the initia-
tion of cell death (22).
To drug the Hsp90 networks in cancer (23), several small mol-
ecule ATPase antagonists have been developed from the ansamy-
cin antibiotic geldanamycin (GA) (14, 24) or, more recently, from 
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purine or resorcinol structures (25). Backed by encouraging pre-
clinical studies, showing differential activity in tumor cells com-
pared with normal tissues, Hsp90-based therapy has now reached 
the clinic. However, despite the expectation that these agents may 
function as genuine pathway inhibitors, their activity in cancer 
patients has been modest or not observed at all (26).
In this study, we tested the impact of network subcellular com-
partmentalization in dictating the activity of Hsp90 inhibitors. We 
report the design of Gamitrinibs (GA mitochondrial matrix inhib-
itors), which are, to our knowledge, the first class of fully synthetic, 
combinatorial small molecules, targeting the Hsp90 network in 
tumor mitochondria (22).
Results
Selective targeting of the mitochondrial Hsp90 network. We began this 
study by designing what we believe to be a new class of small mol-
ecule Hsp90 antagonists selectively targeted to mitochondria, i.e., 
Gamitrinibs. The chemical synthesis of Gamitrinib is described in 
detail in the Supplemental Data and Supplemental Figure 1 (sup-
plemental material available online with this article; doi:10.1172/
JCI37613DS1). The structure of Gamitrinib is combinatorial 
(Figure 1A) and contains a benzoquinone ansamycin backbone 
derived from the Hsp90 inhibitor 17-(allylamino)-17-demethoxy-
geldanamycin (17-AAG) (14), a linker region on the C17 position, 
and a mitochondrial targeting moiety, either provided by 1 to 4 
tandem repeats of cyclic guanidinium (27) (Gamitrinib-G1–G4) 
or triphenylphosphonium (28) (Gamitrinib–TPP-OH) (Figure 
1A). By molecular dynamics simulation, the 17-AAG portion of 
Gamitrinib is predicted to make contacts with the Hsp90 ATPase 
pocket, whereas the mitochondriotropic guanidinium module 
is excluded from the binding interface, pointing outside of the 
ATPase pocket toward the solvent (Figure 1B, top panel). In the 
predicted docking structure, the binding arrangement of Gami-
trinibs to Hsp90 closely follows that of GA (29), with root mean 
Figure 1
Structure of Gamitrinibs. (A) Combinatorial modular design. The indicated individual modules of Gamitrinibs (mitochondrial targeting, linker, and 
Hsp90 inhibition) are indicated. G-G1, Gamitrinib-G1; G-TPP, Gamitrinib–TPP-OH; TBDPS, tert-butyldiphenylsilyl. (B) A 3D docking model of 
Gamitrinib-G1 with Hsp90 N-domain (top panel). The side chains of contact sites are labeled and in color. An overlay of Gamitrinib-G1 (red) and 
GA (gray) in the ATPase pocket of Hsp90 (bottom panel).
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square deviation of heavy atoms of the 17-AAG region being 0.5 Å 
(Figure 1B, bottom panel).
We next carried out 2 experiments to test whether the addition 
of a mitochondriotropic moiety reduced the ability of the 17-AAG 
backbone to bind Hsp90 and block its chaperone function. In 
previous studies, modifications of the C17 position of GA or 
17-AAG did not affect inhibition of the chaperone ATPase cycles. 
Consistent with this, increasing concentrations of GA effectively 
competed with GA affinity beads for binding to Hsp90 in a tumor 
cell lysate (Figure 2A, left panel). Similarly, Gamitrinib-G4 dis-
placed Hsp90 from GA affinity beads, albeit less efficiently than 
GA in this assay (Figure 2A, right panel). Conversely, increasing 
concentrations of both unconjugated 17-AAG and Gamitrinib-G4 
capably inhibited Hsp90 chaperone activity (Figure 2B), using a 
purified client protein assay, i.e., Chk1 reconstitution assay (30). 
We next asked whether the combinatorial design of Gamitrinibs 
allowed their accumulation in isolated tumor mitochondria. For 
these experiments, we used a spectrophotometric approach cou-
pled to gradient density ultracentrifugation of cellular extracts 
for isolation of purified mitochondria (Figure 2C). In prelimi-
nary studies, we found that at a drug concentration of 0.2 M, 
unconjugated 17-AAG exhibited 2 peaks of absorption at 338 nm 
(absorption, 2.448) and 533 nm (absorption, 0.182), whereas peak 
absorption for Gamitrinib-G4 was at 338 nm (absorption, 2.124) 
and 543 nm (absorption, 0.138), respectively. Thus, an absorbance 
at 338 nm was chosen for all subsequent detection stud-
ies of Gamitrinibs. Using these experimental conditions, 
Gamitrinib-G4 was readily detected at a 1–1.5 M interface, 
corresponding to isolated mitochondria after gradient den-
sity ultracentrifugation (Figure 2, C and D). In contrast, 
17-AAG did not localize to the mitochondrial interface as 
compared with untreated samples (Figure 2, C and D) in 
agreement with previous observations (22). Using a simi-
lar approach, all Gamitrinibs accumulated comparably in 
isolated tumor mitochondria, regardless of the structure or 
composition of their mitochondriotropic moieties (Figure 2E).
Gamitrinibs induce sudden mitochondrial permeability transition. 
When added to isolated tumor mitochondria, Gamitrinibs caused 
immediate loss of inner mitochondrial membrane potential, all 
with comparable efficiency, regardless of their different mito-
chondriotropic moieties (Figure 3A). In contrast, unconjugated 
Hsp90 inhibitors, including GA, 17-AAG, or 17-(dimethylamino-
ethylamino)-17-demethoxygeldanamycin (DMAG), did not affect 
mitochondrial membrane potential (Figure 3A). Next, we asked 
whether this response was specific for inhibition of Hsp90 chap-
erone activity inside mitochondria. Consistent with the data pre-
sented above, Gamitrinibs (Gamitrinib-G4 or –TPP-OH) suddenly 
depolarized tumor mitochondria, and this reaction was partially 
reversed by cyclosporine A (CsA), an inhibitor of the immunophilin 
CypD (Figure 3B). In contrast, treatment of tumor mitochondria 
with the mitochondriotropic moieties of Gamitrinbs, tetraguani-
dinium (TG-OH) or TPP-OH plus unconjugated 17-AAG or GA 
had no effect on mitochondrial membrane potential, with or with-
out CsA (Figure 3B).
Loss of mitochondrial membrane potential followed by rupture 
of the outer membrane and release of cytochrome c are hallmarks 
of mitochondrial permeability transition (21) and the molecular 
prerequisites for the initiation of the intrinsic pathway of apop-
tosis (21). To further test this model, we examined the ability of 
Gamitrinibs to induce cytochrome c release from isolated tumor 
Figure 2
Inhibition of Hsp90 chaperone activity. (A) Competition with GA 
affinity beads. GA (left panel) or Gamitrinib-G4 (right panel), 
at the indicated concentrations, were incubated with aliquots 
of SKBr3 tumor cell lysates followed by affinity purification of 
Hsp90 using GA affinity beads. Data are densitometric quantifi-
cations of scanning and image analysis of Hsp90 bands visual-
ized by Western blotting. (B) Inhibition of Chk1 kinase activity. 
17-AAG or Gamitrinib-G4 (1–10 μM) were analyzed for modula-
tion of Chk1-dependent phosphorylation of Cdc25. Densitomet-
ric quantification of protein bands (right panel). (A and B) Data 
are representative of 2 independent experiments with identical 
results. (C) Accumulation of Gamitrinib in mitochondria. Cel-
lular extracts were loaded with vehicle (None), unconjugated 
17-AAG, or Gamitrinib-G4 and analyzed before (left panel) or 
after gradient density ultracentrifugation (right panel). The posi-
tion of the 1–1.5 M interface corresponding to isolated mito-
chondria is indicated. (D) Quantification of mitochondrial accu-
mulation. Mitochondria isolated from HeLa cells were incubated 
with 17-AAG, Gamitrinib-G4, or vehicle and analyzed using 
absorbance. Data are the mean ± SEM (n = 3). (E) Mitochon-
driotropic properties of all Gamitrinibs. Mitochondria isolated 
from Raji cells were incubated with the indicated Gamitrinibs or 
vehicle and analyzed by absorbance. Data are from a represen-
tative experiment out of 2 independent determinations.
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mitochondria. In these experiments, all Gamitrinibs induced rapid 
(20 minute) discharge of mitochondrial cytochrome c in the super-
natant, whereas unconjugated 17-AAG was ineffective (Figure 3C). 
Because Gamitrinib-induced loss of mitochondrial membrane 
potential was sensitive to CsA (Figure 3B), we next asked whether 
pharmacologic inhibition of CypD prevented the accumulation of 
the compound(s) in mitochondria. Gamitrinib-G4 readily accu-
mulated in isolated tumor mitochondria, within the same time 
interval of induction of organelle permeability transition (Figure 
3D), in agreement with the data presented above (Figure 2, C–E). 
In these experiments, preincubation of isolated mitochondria with 
CsA, under the same conditions used to antagonize permeability 
transition (Figure 3B), did not reduce Gamitrinib accumulation in 
mitochondria (Figure 3D).
Additional derivatives of 17-AAG as well as purine- and isoxa-
zole resorcinol–based Hsp90 antagonists (Supplemental Figure 2) 
have been recently developed, with promising anticancer activity in 
preclinical studies (25). Therefore, it was of interest to test whether 
these GA-modified or non–GA-based Hsp90 antagonists affected 
mitochondrial integrity. Gamitrinib-G4 induced sudden and com-
plete discharge of cytochrome c from tumor mitochondria (Figure 
3E), in agreement with the data above. In contrast, increasing con-
centrations of 17-AAG, hydroquinone derivative of 17-AAG (IPI-
504), purine analog (BIIB021), or isoxazole (NVP-AUY922) Hsp90 
inhibitors (25) had no effect on cytochrome c release (Figure 3E).
Induction of mitochondrial apoptosis by Gamitrinibs. A 3-hour expo-
sure of lung adenocarcinoma H460 cells to Gamitrinib-G3 or -G4 
was sufficient to produce concentration dependent (IC50 ~0.5 μM) 
and complete loss of cell viability (Figure 4A, left panel) in the 
tumor cell population. Within this time frame, Gamitrinib-G1 or 
17-AAG had no effect and Gamitrinib-G2 or Gamitrinib–TPP-OH 
had intermediate activity (Figure 4A, left panel). By 24 hours, all 
Gamitrinibs had comparably killed the entire tumor cell popula-
tion, whereas 17-AAG had only partially reduced cell viability or 
cell proliferation (Figure 4A, right panel). As Gamitrinibs all com-
parably induce membrane depolarization of isolated mitochon-
dria (Figure 3A), these data suggest that the Gamitrinib-G4 and 
-G3 moieties provide more efficient intracellular drug uptake, as 
compared with Gamitrinib-G1 and -G2 structures in vivo.
We next studied the cell death phenotype induced by Gami-
trinibs. Treatment of H460 cells with Gamitrinib-G4 resulted in 
rapid loss of mitochondrial membrane potential in the whole 
tumor cell population, pronounced effector caspase activity, and 
cell death consistent with genuine mitochondrial apoptosis (Fig-
ure 4B). In contrast, vehicle alone had no effect on mitochon-
drial integrity or cell viability (Figure 4B). Proapoptotic Bcl-2 
family proteins regulate mitochondrial cell death, in particular 
permeabilization of the outer membrane (21). Therefore, we next 
asked whether Gamitrinib-induced tumor cell killing was depen-
dent on Bax, a multidomain proapoptotic Bcl-2 protein required 
for many cell death responses (31). In these experiments, Gami-
trinib-G4 comparably induced concentration-dependent kill-
ing of wild-type or Bax–/– colorectal cancer HCT116 cells (Fig-
ure 4C). Consistent with these data, Gamitrinib-G4 exhibited a 
broad spectrum of anticancer activity, and comparably killed a 
molecularly and genetically heterogeneous panel of tumor cell 
types, representative of epithelial and hematologic malignancies 
(Table 1). In contrast, exposure of these cells to the mitochon-
driotropic moiety (TG-OH) plus unconjugated 17-AAG had no 
effect on cell viability (Table 1).
Figure 3
Mitochondrial dysfunction. (A) Mitochondrial membrane depolarization. Tetramethylrhodamine methyl ester–loaded (TMRM-loaded) HeLa cell 
mitochondria treated with Gamitrinibs or the various indicated agents (1 μM) were analyzed for changes in fluorescence emission. (B) Analysis 
of individual mitochondriotropic moieties. TMRM-loaded HeLa cell mitochondria were incubated with 1.5 μM 17-AAG plus tetraguanidinium 
(TG-OH) or Gamitrinib-G4 (left panel) or 0.7 μM GA plus TPP-OH or Gamitrinib–TPP-OH (right panel) and analyzed for changes in fluorescence 
emission in the presence or absence of CsA (5 μM). Arrows indicate point of addition. (C) Cytochrome c (Cyto c) release. Mitochondria isolated 
from HeLa cells treated with Gamitrinibs or 17-AAG (20 minutes) were analyzed for cytochrome c release in supernatants (S) or pellets (P). 
Cox-IV or Ran was used as a mitochondrial or cytosolic marker, respectively. Reactivity of the antibody to Ran with isolated cytosolic extracts 
(C) was used as a control. (D) Mitochondrial accumulation. Isolated HeLa cell mitochondria were incubated with vehicle or Gamitrinib-G4 in the 
presence or absence of CsA and analyzed using absorbance. Data are the mean ± SEM. (E) Analysis of nontargeted Hsp90 inhibitors. Isolated 
HeLa cell mitochondria were incubated with increasing concentrations of the various indicated agents for 3 hours and analyzed for cytochrome c 
release. Data are representative of 2 independent experiments.
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Mitochondriotoxic mechanism of action of Gamitrinibs. Current Hsp90 
inhibitors predominantly cause cell cycle arrest in most tumor cell 
types, followed by a variable degree of apoptosis after a prolonged 
drug exposure of 48–72 hours. To test whether Gamitrinibs had 
a similar mechanism of action, we used breast adenocarcinoma 
SKBr3 cells, which are considered sensitive to Hsp90 inhibition. 
Gamitrinib-G4, Gamitrinib–TPP-OH, or unconjugated 17-AAG all 
resulted in comparable reduction of metabolic activity in SKBr3 
cells by 48 hours and throughout a 96-hour interval after treatment 
(Figure 5A). However, most SKBr3 cells treated with 17-AAG were 
still alive after 72 hours, as shown using Trypan blue exclusion and 
light microscopy (Figure 5B). In contrast, Gamitrinibs 
were cytotoxic, and a 24-hour treatment was sufficient 
to cause nearly complete killing of the entire tumor cell 
population (Figure 5B). When analyzed in a model of 
long-term tumorigenicity, a brief (4-hour) exposure of 
H460 cells to Gamitrinib-G4 completely abolished colony 
formation in soft agar after a 2-week incubation (Figure 
5C). In contrast, 17-AAG had no effect on tumorigenic-
ity under the same conditions, and vehicle alone did not 
decrease H460 colony formation in soft agar (Figure 5C).
A hallmark of Hsp90 inhibition by conventional small 
molecule antagonists is the degradation of client proteins 
in the cytosol, with concomitant upregulation of Hsp70 
chaperone levels. Consistent with this, treatment of cer-
vical carcinoma HeLa cells with 17-AAG resulted in effi-
cient loss of Hsp90 client proteins, Akt and Chk1 (14), and 
increased expression of Hsp70 (32), as analyzed by West-
ern blotting (Figure 5D). At variance with this phenotype, 
incubation of HeLa cells with Gamitrinib-G4 had no effect 
on the levels of Hsp90 client proteins in the cytosol and did 
not result in upregulation of Hsp70 levels (Figure 5D).
Previous studies have shown that mitochondrial Hsp90 
chaperones physically associate with the permeability pore 
component, CypD (21), and prevent its opening by a pro-
tein folding mechanism that antagonizes the initiation 
of cell death. Consistent with this model, siRNA silenc-
ing of CypD in H460 cells (Figure 5E, inset) markedly attenuated 
Gamitrinib-G4–induced tumor cell killing (Figure 5E). In contrast, 
a nontargeted siRNA was without effect (Figure 5E, inset) and 
17-AAG did not reduce H460 cell viability within the same time 
interval in the presence or absence of CypD (Figure 5E). Collectively, 
these data demonstrate that Gamitrinibs exhibit what we believe 
to be a unique, mitochondriotoxic mechanism of action, which 
involves CypD induction of organelle permeability transition, with-
out affecting global Hsp90 homeostasis outside of mitochondria.
Selectivity of Gamitrinib anticancer activity. Because mitochondria 
of most normal tissues do not contain Hsp90 chaperones, it was 
Figure 4
Gamitrinib-mediated anticancer activity. (A) Time course. H460 cells 
treated with the indicated concentrations of Gamitrinibs or 17-AAG 
were analyzed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay after 3 hours (left panel) or 24 hours (right 
panel). Data are the mean ± SD (n = 2). (B) Caspase-associated cell 
death. H460 cells, treated with Gamitrinib-G4 or vehicle for 4 hours, 
were labeled with JC-1 and analyzed for loss of mitochondrial mem-
brane potential by changes in FL2/FL1 fluorescence ratio (top panel) 
or Asp-Glu-Val-Asp-ase (DEVDase) (caspase) activity (bottom panel) 
using multiparametric flow cytometry. The percentage of cells in each 
quadrant is indicated. PI, propidium iodide. (C) Insensitivity to Bax. 
Wild-type or Bax–/– HCT116 cells were incubated with the indicated 
increasing concentrations of Gamitrinib-G4 and analyzed after 6 hours 
using MTT assay. Data are representative of 2 experiments.
Table 1
Broad spectrum of Gamitrinib-G4 anticancer activity
Cell line Origin Gamitrinib-G4  17-AAG/ 
  IC50 (μM) TG-OH IC50
A431 Squamous cell carcinoma 4.0 26.8
MDA-MB-231 Breast adenocarcinoma (ER–) 17.0 40.4
U87MG Glioblastoma multiformis 12.4 >200.0
MCF-7 Breast adenocarcinoma (ER+) 15.2 103.4
H1975 Lung adenocarcinoma 14.2 >200.0
DU145 Prostate adenocarcinoma 12.5 >200.0
H460 Lung adenocarcinoma 8.2 >200.0
HCT116 Colorectal adenocarcinoma 19.0 >200.0
K562 Chronic myelogenous leukemia  7.5 81.2
 in blast crisis
HL60 Myeloblastic leukemia 9.2 >200.0
THP-1 Monoblastic leukemia 8.2 >200.0
Raji B cell lymphoma 3.1 >200.0
Mean  10.9 ± 1.4 N.D.
The indicated tumor cell lines were incubated with increasing concentrations of 
Gamitrinib-G4 or unconjugated 17-AAG plus tetraguanidinium (TG-OH) mitochon-
driotropic moiety (0–25 μM) and analyzed after 6 hours using MTT assay. Data 
are representative of 2 experiments. The indicated IC50 (μM) values refer to the 
concentrations of Gamitrinib-G4 that produce 50% tumor cell killing. ER, estrogen 
receptor. N.D., not determined.
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of interest to test whether Gamitrinibs were selective anticancer 
agents. Exposure of normal mitochondria isolated from WS-1 
human fibroblasts to Gamitrinib-G4 or 17-AAG induced only 
a modest decrease in mitochondrial membrane potential in the 
presence or absence of CsA (Figure 6A). Similarly, Gamitrinibs did 
not induce discharge of cytochrome c from normal mitochondria 
(Figure 6B). As control, mitochondria isolated from HeLa cells 
were nearly completely depleted of cytochrome c after treatment 
with Gamitrinib-G1 but not 17-AAG (Figure 6B). Validating the 
specificity of these results, Gamitrinib-G4 readily accumulated in 
isolated normal mouse liver mitochondria, and this response was 
also unaffected by CypD inhibition with CsA (Figure 6C). Similar 
to the phenotype observed with tumor mitochondria, nontargeted 
17-AAG did not accumulate in normal mitochondria (Figure 6C).
Consistent with this inability to induce mitochondrial perme-
ability transition in normal cells, concentrations of Gamitrinib 
that readily killed tumor cell types did not cause cell death of nor-
mal primary cell types, including bovine aortic endothelial cells or 
intestinal epithelial cells, and only modestly reduced the viability 
of normal human foreskin fibroblasts or human umbilical vein 
endothelial cells (Figure 6D). Similarly, comparable concentra-
tions of 17-AAG had no effect on the viability of the various nor-
mal human cells tested (Figure 6D).
Gamitrinib inhibition of tumor growth 
in vivo. Systemic administration of 
Gamitrinib-G4 to mice inhibited 
the growth of established human 
leukemia (Supplemental Figure 
3A), breast (Supplemental Figure 
3B), and lung (Figure 7A) xenograft 
tumors in vivo. In contrast, com-
parable concentrations of 17-AAG 
had no effect on human lung can-
cer growth in mice (Figure 7A, top 
panel). Gamitrinibs carrying differ-
ent mitochondriotropic moieties, 
i.e., Gamitrinib-G1 or –TPP-OH, 
also comparably inhibited lung can-
cer growth in vivo (Figure 7A, bot-
tom panel). Tumors harvested from 
Gamitrinib-treated animals exhibit-
ed extensive apoptosis in situ (Figure 
7B) and discharge of cytochrome c in 
the cytosol (Figure 7C), suggestive 
of treatment-related mitochondrial 
dysfunction in vivo. At the concen-
trations used, the various Gamitrin-
ibs did not cause significant animal 
weight loss throughout the treat-
ment (Figure 7D). For preliminary 
toxicology experiments, organs, 
including brain, small and large 
intestine, heart, spleen, liver, pancre-
as, stomach, lung and kidneys, were 
collected from mice in the various 
treatment groups and analyzed his-
tologically. In these studies, organs 
harvested from Gamitrinib-treated 
animals were histologically unre-
markable compared with the vehicle 
group, with no changes in general architecture and no evidence of 
inflammation or liver steatosis (Supplemental Figure 4).
Discussion
In this study, we reported the combinatorial structure and activity 
of Gamitrinibs, which we believe to be the first class of small mol-
ecules engineered to selectively target a compartmentalized Hsp90 
network in tumor mitochondria (22). Gamitrinibs efficiently accu-
mulate in mitochondria, trigger sudden and irreversible organelle 
permeability transition, and induce exceedingly fast (~1 hour) and 
complete tumor cell killing by apoptosis. In turn this results in 
inhibition of tumor growth in vivo, with no detectable toxicity for 
normal cells or tissues. Differently from current Hsp90 antago-
nists, Gamitrinibs exhibit what we believe to be a novel mechanism 
of action, exclusively centered on induction of mitochondrial dys-
function, i.e., mitochondriotoxic, and do not affect global Hsp90 
homeostasis outside of mitochondria. For these combined proper-
ties, we believe Gamitrinibs are novel, attractive anticancer agents, 
suitable for human testing.
New strategies for cancer drug discovery are urgently needed to 
remedy the high cost, low yield, and high risk of failure of tradi-
tional, target-centric drug discovery (7). An integrated, pathway-
oriented approach that aims at cancer networks in their globality, 
Figure 5
Gamitrinibs induction of mitochondrial apoptosis. (A) Comparison with 17-AAG. SKBr3 cells were 
treated with Gamitrinibs or 17-AAG (10 μM) for the indicated time intervals and analyzed using MTT 
assay. Data are representative of at least 2 independent experiments. (B) Tumor cell killing. SKBr3 
cells treated with vehicle, Gamitrinib-G4, Gamitrinib–TPP-OH, or 17-AAG (10 μM), for the indicated 
time intervals, were analyzed by Trypan blue exclusion. Data are the mean ± SEM (n = 3). (C) Colony 
formation. H460 cells treated with vehicle, 17-AAG (50 μM), or Gamitrinib-G4 (50 μM) for 4 hours 
were analyzed for colony formation in soft agar after 2 weeks. Representative microscopy fields are 
shown. Original magnification, ×40. (D) Client protein modulation. HeLa cells treated with the indicated 
Gamitrinibs, 17-AAG (5 μM), or vehicle were analyzed for modulation of Hsp90 client proteins Akt and 
Chk1 in the cytosol or changes in expression of Hsp70 after 24 hours by Western blotting. (E) Require-
ment for CypD in Gamitrinib anticancer activity. H460 cells transfected with control (closed symbols) 
or CypD (open symbols) siRNA were treated with 17-AAG (circles) or Gamitrinib-G4 (squares) and 
analyzed using MTT assay after 6 hours. Data are the mean ± SEM (n = 3). The inset shows Western 
blotting of CypD knockdown by siRNA.
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instead of individual genes in isolation (5), has recently emerged 
as a potentially attractive alternative to drug discovery (11). How-
ever, this may still not be sufficient to capture the complexity of 
cancer networks, as these pathways are not randomly assembled 
in tumor cells but compartmentalized in specialized, semiautono-
mous microenvironments (33). The data presented here, based on 
the combinatorial delivery of a well-known Hsp90 inhibitory moi-
ety (17-AAG) (14) to a specialized compartment (mitochondria) 
(22), demonstrate that incorporating subcellular targeting in drug 
design is not only feasible but also leads to the generation of effec-
tive agents with specificities and mechanisms of action, which we 
believe to be novel.
Similar to the mitochondriotropic design of Gamitrinibs, the 
idea of manipulating mitochondrial homeostasis (21) for novel 
cancer therapeutics has been aggressively pursued (34). Small mol-
ecule modifiers of pro- or antiapoptotic Bcl-2 family proteins that 
shift the balance in mitochondrial outer membrane permeability 
and trigger the release of apoptogenic proteins in the cytosol (35) 
have now reached the clinic (34). However, Gamitrinibs are differ-
ent from these agents, as they directly target a potential upstream 
step in mitochondrial permeability transition, resulting in imme-
diate depolarization of the inner membrane and sudden collapse 
of organelle integrity. Because this pathway is unaffected by pro-
apoptotic regulators of outer membrane permeability, e.g., Bax 
(35), Gamitrinibs may be less sensitive to mechanisms conferring 
resistance to Bcl-2 modifier drugs (34), including upregulation of 
antiapoptotic Mcl-1 (36) or activation of parallel pathways of cyto-
chrome c release (37).
The molecular requirements of mitochondrial permeability 
transition as a pathophysiological antecedent of apoptotic cell 
death have not been completely elucidated (21). Molecules that 
had long been held as essential constituents of a permeability 
transition pore, including the voltage-dependent anion channel 
(VDAC) (38) or the adenine nucleotide translocator (ANT) (39), 
turned out to be dispensable for mitochondrial cell death. Con-
versely, there is agreement that the matrix immunophilin CypD is 
essential to execute mitochondrial permeability transition, espe-
cially in response to certain cell death stimuli, for instance, Ca2+ 
overload or oxidative stress (40–42). Here, Gamitrinib-induced 
anticancer activity was dependent on CypD function, with respect 
to both depolarization of the inner membrane and tumor cell kill-
ing. Whether this reflects a role of CypD in an organized perme-
ability transition pore (21) or its dynamic assembly in clusters 
of unfolded mitochondrial proteins that mediate conductance 
across the mitochondrial membrane (43) remains to be deter-
mined. However, the latter model better explains a cytoprotective 
function of mitochondrial Hsp90 chaperones (22), which may 
involve refolding of unfolded protein clusters generated by oxi-
dative stress, with suppression of CypD-dependent pore opening 
(43). In this context, inhibition of mitochondrial chaperone activ-
ity by Gamitrinibs would acutely remove this steady-state cyto-
protective mechanism, unrestraining an organelle unfolded pro-
tein response that culminates with CypD-dependent permeability 
transition and irreversible mitochondrial collapse (43). Although 
this cell death pathway has the hallmarks of mitochondrial apop-
tosis, it was only minimally affected by pharmacologic caspase 
inhibitors (data not shown), thus suggesting that Gamitrinib 
anticancer activity may also escape compensatory mechanisms 
downstream of mitochondria, typically involving upregulation 
of inhibitor of apoptosis (IAP) proteins (44).
Several small molecule Hsp90 antagonists based on the structure 
of GA (17-AAG, IPI-504) or purine or resorcinol (BIIB021, NVP-
AUY922) have been recently developed (25). As shown here, none 
of these agents, even at high concentrations, affected mitochondri-
al integrity, as quantified by analysis of mitochondrial inner mem-
brane potential or cytochrome c release. This likely reflects their 
inability to cross the mitochondrial membrane(s) or accumulate in 
the organelle, which was anticipated in earlier fluorescence local-
ization studies with FITC-coupled 17-AAG (22). In the absence of 
mitochondrial targeting, the different Hsp90 antagonists primar-
ily induce a cytostatic phenotype in tumor cells (45, 46), charac-
terized by G1 and/or G2/M cell cycle arrest. This is due to loss of 
proliferation-associated Hsp90 client proteins in the cytosol (14) 
and a variable, but always partial degree of apoptosis after pro-
tracted drug exposure. Cell-type specific differences in the sensi-
tivity to GA- or non–GA-based Hsp90 antagonists have also been 
Figure 6
Selectivity of Gamitrinib anticancer activity. (A) Mitochondrial mem-
brane potential. TMRM-loaded mitochondria isolated from WS-1 nor-
mal human fibroblasts were incubated with Gamitrinib-G4 or 17-AAG 
plus the uncoupled mitochondriotropic moiety TG-OH and analyzed 
for changes in inner membrane potential in the presence or absence 
of CsA. (B) Cytochrome c release. Mitochondria isolated from normal 
HFF fibroblasts were treated with Gamitrinibs or 17-AAG and analyzed 
by Western blotting. HeLa cells were used as control. Cox-IV or Ran 
was used as a mitochondrial or cytosolic marker, respectively. Reac-
tivity of the antibody to Ran with isolated cytosolic extracts from HeLa 
or HFF cells was used as a control. (C) Mitochondrial accumulation. 
Isolated normal mouse liver mitochondria were incubated with vehicle, 
17-AAG, or Gamitrinib-G4 in the presence or absence of CsA and ana-
lyzed using absorbance. Data are the mean ± SEM. (D) Analysis of cell 
viability. Human fibroblasts (HFF, black line), bovine aortic endothelial 
cells (brown line), intestinal epithelial cells (red line), or human umbili-
cal vein endothelial cells (green line) were treated with Gamitrinib-G4 
(solid lines) or 17-AAG (dashed lines) and analyzed using MTT assay 
after 24 hours. Data are representative of 2 experiments.
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reported that may further affect their anticancer activity (45, 46). 
Conversely, mitochondrial targeting radically changed the activ-
ity profile of these agents, e.g., 17-AAG, as Gamitrinibs exclusively 
exhibited a cytotoxic phenotype, induced nearly complete tumor 
cell killing within 1 hour of treatment, and showed comparable 
efficacy against a broad spectrum of tumor cell types, regardless 
of molecular or genetic makeup. Further reinforcing their unique 
mechanism of action, Gamitrinibs did not affect the homeostatic 
functions of Hsp90 in the cytosol, leaving untouched the levels 
of various client proteins, without upregulation of Hsp70 expres-
sion. These observations reaffirm the selectivity of Gamitrinibs 
solely for the mitochondrial pool of Hsp90 (22) and suggest that 
this pathway may be unaffected by a third tier of compensatory 
mechanisms that are invariably induced by nontargeted Hsp90 
inhibitors, including upregulation of cell survival molecules, for 
instance, Hsp70 (47), activation of oncogenic kinases (48), and 
paradoxical enhanced metastatic dissemination in vivo (49).
The mechanism of action of Gamitrinibs is also distinct from 
that of the peptidomimetic Shepherdin (50), which also inhibits 
Hsp90 ATPase activity and accumulates in mitochondria (22). 
Modeled on the binding interface between Hsp90 and the client 
protein, survivin (50), Shepherdin produces a dual phenotype of 
degradation of Hsp90 client proteins in the cytosol (50) as well 
as induction of mitochondrial permeability transition (22). These 
data suggest that the cytosolic transfer of Shepherdin may be 
long enough to mediate inhibition of 
Hsp90 activity in the cytosol followed 
by mitochondrial accumulation. Con-
versely, 2 structurally unrelated small 
molecule moieties, TPP-OH (28) or 
tandem repeats of cyclic guanidinium 
(27), mediated fast mitochondrial 
targeting of Gamitrinibs, which pre-
vented inhibition of cytosolic Hsp90. 
These data have important practical 
implications for drug delivery in vivo. 
For their rapid localization to mito-
chondria, Gamitrinibs are expected to 
escape sequestration by the high con-
centrations of Hsp90 in the cytosol 
(1%–2% of total cellular protein con-
tent), which may otherwise decrease 
the efficiency of intramitochondrial 
accumulation.
Despite their ability to disrupt a 
fundamental mechanism of mito-
chondrial integrity (21), Gamitrinibs 
are well tolerated in vivo and have no 
effect on mitochondrial permeabil-
ity transition of various normal cell 
types in culture. Considerably more 
work is needed to establish the full 
toxicity profile of these agents in vivo, 
but this observed nontoxicity may 
reflect the nearly exclusive presence of 
Hsp90 chaperones in mitochondria of 
tumors but not most normal tissues 
in vivo (22). This differential local-
ization implies a broad exploitation 
of a cytoprotective mechanism ide-
ally suited to favor cellular adaptation to noxious environments, 
in particular high levels of oxidative stress, which is invariably 
associated with tumor growth. Consistent with this model, mito-
chondrial TRAP-1 (20) has been recently implicated in protection 
from apoptosis induced by oxidative stimuli (51, 52). Although 
mitochondrial chaperones have been detected in certain normal 
tissues, for example, brain and testis, in which enhanced cytopro-
tection may be required for normal homeostasis, their affinity for 
ATPase pocket antagonists is likely 100-fold lower than that of 
tumor-associated Hsp90, thus adding to a potentially favorable 
therapeutic window of Gamitrinibs (53).
In summary, we have developed what we believe to be a novel, 
combinatorial drug design for the delivery of pathway inhibitors, 
i.e., Hsp90 ATPase antagonists (14), to specialized subcellular com-
partments. This drug engineering paradigm is cost-effective, ame-
nable to further chemical optimization, and broadly applicable to 
structurally unrelated Hsp90 antagonists (25) and mitochondrio-
tropic moieties. Although applied to the Hsp90 network, a similar 
approach could be also envisioned to selectively target other com-
partmentalized cancer networks (33). Functionally, the first prod-
ucts of this combinatorial approach, i.e., Gamitrinibs, exhibited radi-
cally different properties compared with their parental, nontargeted 
Hsp90 inhibitors, with respect to specificity, profile of anticancer 
activity, and mechanism of action. Therefore, such compartmental-
ized, pathway-oriented drug discovery can unlock novel properties 
Figure 7
Gamitrinibs anticancer activity in vivo. (A) Kinetics of xenograft tumor growth. SCID/beige mice car-
rying H460 lung adenocarcinoma xenograft tumors (100–150 mm3) were treated with Gamitrinib-G4 
or 17-AAG (top panel), with a dose escalation regimen as described in Supplemental Data, or with 
Gamitrinib-G1 or Gamitrinib–TPP-OH (bottom panel). Tumor volume was measured with a caliper. 
(B) Induction of apoptosis in vivo. Tumor specimens from vehicle- or Gamitrinib-treated tumors 
were analyzed for internucleosomal DNA fragmentation in situ (using TUNEL staining), and posi-
tive cells were quantified (bottom panel). Original magnification, ×400. ***P < 0.0001. Data are the 
mean ± SEM (A and B). (C) Mitochondrial dysfunction in vivo. Cytosolic fractions from H460 xeno-
graft tumors harvested from vehicle- or Gamitrinib-G4–treated animals were analyzed by Western 
blotting. Two mice per group were tested and the animal number is shown. (D) Animal weight. 
Mice treated with the various Gamitrinibs, 17-AAG, or vehicle were analyzed for percentage weight 
change at the end of the experiment. Data are the mean ± SEM.
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of existing agents (3, 6), with promising preclinical activity, while 
limiting costly and low-yield new drug screenings (5).
Methods
Reagents. Complete Mini EDTA-free protease inhibitor cocktail was from 
Roche. 17-AAG was purchased from LC Laboratories. CsA was obtained 
from Sigma-Aldrich. Antibodies to cytochrome c (Clontech), Cox-IV (Clon-
tech), CypD (peptidylprolyl isomerase F, PPIF; Calbiochem), Chk1 (Santa 
Cruz Biotechnology Inc.), Ran (Novus Biologicals), Hsp70 (AbCam), Akt 
(Cell Signaling Technology Inc.), β-actin (Sigma-Aldrich), and GAPDH 
(Advanced ImmunoChemical Inc.) were used. siRNA oligonucleotides to 
CypD or control nontargeted siRNA were obtained from Dharmacon and 
were characterized previously (22).
Cell lines. Human chronic myelogenous leukemia in blast crisis K562, 
B lymphoblastoid Raji, monocytic leukemia THP-1, myeloblastic leukemia 
HL-60, breast adenocarcinoma MDA-MB-231 (ER-negative) or MCF-7 
(ER-positive), lung adenocarcinoma H460 and H1975, prostate adenocar-
cinoma DU145, glioblastoma U87MG, colon adenocarcinoma HCT-116, 
and cervical carcinoma HeLa cells were obtained from ATCC and were 
maintained in culture according to the supplier’s specifications. The nor-
mal human cell types, foreskin fibroblast HFF, epithelial fibroblast WS-1, 
and intestinal epithelial INT were also obtained from ATCC. Bovine aortic 
endothelial cells and human umbilical vein endothelial cells were isolated 
and maintained in culture according to published protocols (54).
Isolation of mitochondria and mitochondriotropic property of drugs. Mitochon-
dria were isolated from HeLa cells as described previously (22). Briefly, HeLa 
cells were harvested and washed with TD buffer (135 mM NaCl, 5 mM KCl, 
25 mM Tris, pH 7.6). The cell pellet was suspended in 1 volume of CaRSB 
buffer (10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris, pH 7.5, protease inhibi-
tor) and incubated for 5 minutes at 0°C. Swelled cells were homogenized 
in a Dounce grinder and immediately mixed with 1.5 volume of MS buf-
fer (210 mM mannitol, 70 mM sucrose, 5 mM Tris, pH 7.6, 5 mM EDTA). 
Nuclei and other cellular debris were removed by centrifugation at 600 × g 
for 15 minutes. Samples were further incubated with 200 μM Gamitrinib 
or 17-AAG per 2,600 μg mitochondria for 5 minutes at 0°C, and treated 
mitochondria were reisolated by centrifugation at 6,000 × g for 10 minutes. 
The mitochondrial pellet was suspended in MS buffer and applied onto a 
1 M/1.5 M sucrose step gradient in 10 mM Tris, 5 mM EDTA, pH 7.6, 2 mM 
DTT, plus protease inhibitors for 1.5 hours of centrifugation at 110,000 × g. 
The mitochondrial bands were isolated, washed in MS buffer, and lysed 
in buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 0.5% IGEPAL 
CA-630, 1 mM EDTA, plus protease inhibitors. Protein concentrations were 
determined using a Bio-Rad protein assay reagent with BSA as a standard. 
Absorbance on comparable protein concentrations was determined at 338 
nm, using a DU530 spectrophotometer (Beckman Coulter). Due to maxi-
mum absorption and signals comparable to those obtained for 17-AAG and 
Gamitrinibs, absorbance at 338 nm was used for drug detection.
Mitochondrial function. For all in vitro experiments, all Gamitrinibs and 
17-AAG were fully dissolved in DMSO. Normal or tumor mitochondria 
(100 μg) were loaded with 0.1 mM tetramethylrhodamine methyl ester 
(TMRM), incubated with Gamitrinibs or 17-AAG, with or without CsA, 
and analyzed continuously for changes in inner membrane potential at 
549 nm excitation and 575 nm emission (Photon Technology Interna-
tional Inc.). The fluorescence intensity after treatment with 2 mM CaCl2 
corresponded to a fully depolarized state. Alternatively, H460 cells were 
labeled with the fluorescent dye JC-1 (Molecular Probes) and analyzed for 
changes in red/green fluorescence (FL2/FL1) ratio after treatment with the 
various agents, using multiparametric flow cytometry. Cytochrome c con-
tent in pellets or supernatants of drug-treated isolated mitochondria was 
determined by Western blotting.
Analysis of Hsp90 function. For GA affinity bead competition experiments, 
SkBr3 breast cancer cells were lysed in TNESV lysis buffer (50 mM Tris-
HCl, pH 7.4, 1% Nonidet P-40, 2 mM EDTA, 100 mM NaCl, 1 mM sodium 
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 20 μg of aprotinin 
and leupeptin per ml). After centrifugation to clarify the supernatant, 
lysates were incubated with 0.00, 0.50, 1.00, or 10.00 μM Gamitrinib or 
0.00, 0.05, 0.10, or 0.50 μM GA on ice for 30 minutes. Lysates (equal pro-
tein amounts) were then subjected to GA affinity bead precipitation and 
blotted for Hsp90 as previously described (55). Hsp90-specific band densi-
ties were determined by scanning and image analysis. GA affinity beads 
were prepared as previously described (55). In other experiments, chap-
erone-dependent glutathione-S-transferase–Chk1 (GST-Chk1) reconsti-
tution was determined as described previously (30). Briefly, each sample 
contained 0.7 μg of resin-bound GST-Chk1 (residues 1–265), 1 μg of puri-
fied human Hsp90α, and the following amounts of other purified chap-
erone proteins: 10 μg Hsp70, 2 μg Hdj1, 2 μg p50cdc37, 0.06 units CK2, and 
2.5 μg p60Hop. Optical densities due to Chk1-dependent phosphorylation 
of Cdc25 in the presence and absence of Gamitrinib or 17-AAG were deter-
mined and plotted as fold activation compared to the sample in which 
chaperone proteins were not added. In some experiments, HeLa cells were 
treated with Gamitrinibs (Gamitrinib-G1–G4) or 17-AAG (5 μM) for 
24 hours and isolated extracts were analyzed for modulation of Akt or 
Hsp70 expression by Western blotting.
Analysis of cell death. Modulation of cell viability was determined using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay (22). For determination of apoptosis, cells were analyzed for caspase 
activity (Asp-Glu-Val-Asp-ase [DEVDase] activity) and plasma membrane 
integrity (propidium iodide) with multiparametric flow cytometry using 
CaspaTag (Intergen) (22).
Xenograft tumor models. All experiments involving animals were approved 
by an Institutional Animal Care and Use Committee at the University of 
Massachusetts Medical School. HL60 (10 × 106) or H460 (4 × 106) cells 
suspended in sterile PBS (200 μl) were injected subcutaneously into both 
flanks of 10-week-old CB17 SCID/beige (Taconic Farms) immunocompro-
mised female mice. Alternatively, MDA-MB-231 cells (5 × 106), suspended 
in 200 μl of 50% Matrigel (BD Biosciences), were used for subcutaneous 
injection in CB17 SCID/beige mice. When superficial tumors reached vol-
umes of 100–150 mm3, animals were randomized in 2 groups (2 tumors/
mouse, 3 animals/group) and treated with vehicle (DMSO) or Gamitrinib 
dissolved in 20% Cremophor EL (Sigma-Aldrich) in PBS by i.p. injection. 
Gamitrinib-G4 was injected i.p. with the following schedule: HL60 xeno-
grafts, 2 mg/kg twice daily; H460 xenografts, 2 mg/kg twice daily for day 0, 
2.5 mg/kg twice daily for day 1, 3.0 mg/kg twice daily for the duration 
of treatment; MDA-MB-231 xenografts, 2 mg/kg twice daily for days 0–2, 
2.5 mg/kg twice daily for days 3–5, and 3 mg/kg twice daily throughout 
the rest of the treatment. 17-AAG was dissolved in 20% Cremophor EL 
and administered as systemic i.p. injections, with the same dose-escalating 
regimen as Gamitrinib-G4 in H460 xenograft studies. Gamitrinib-G1 was 
injected i.p. with following schedule: 30 mg/kg daily for days 0–2 and 50 
mg/kg daily for the rest of treatment. Gamitrinib–TPP-OH was injected i.p. 
at 10 mg/kg daily throughout the duration of the experiment. Tumor mea-
surements were taken daily with a caliper, and tumor volume was calcu-
lated with the formula ([length in millimeters] × [width in millimeters]2)/2. 
Mice in the various treatment groups were weighed at the beginning and at 
the end of each experiment.
In vivo subcellular fractionation. HL60 xenograft tumors from vehicle- or 
Gamitrinib-treated mice were harvested when they reached a volume of 
300–400 mm3, and cytosol fractions were prepared using a Mitochondria 
Isolation Kit (Sigma-Aldrich). Cytochrome c released in the cytosol was 
analyzed by Western blotting.
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In situ internucleosomal DNA fragmentation as shown by TUNEL staining. At 
the end of treatment, tumors were harvested from vehicle- or Gamitrinib-
treated animals, fixed in formalin, embedded in paraffin, and sectioned. 
TUNEL staining was performed with the ApopTag Plus Peroxidase In situ 
Apoptosis Detection Kit (Chemicon), according to the instruction manual, 
as described previously (56). Images were captured using an Olympus 
microscope with an on-line charge-coupled device camera at ×400 mag-
nification (necrotic regions were excluded from the analysis). For quanti-
fication, TUNEL-positive cells were counted in 10 independent areas of a 
×400 magnification field (10 fields/each group).
Histology. Animals in the vehicle or Gamitrinib group were euthanized at 
the end of the experiment, and organs, including brain, colon, heart, kidney, 
liver, lung, pancreas, small intestine, spleen, and stomach, were collected, 
fixed in formalin, and embedded in paraffin. Sections (5 μm) were put on 
high-adhesive slides, stained with H&E, and analyzed by light microscopy.
Statistics. Data were analyzed using the unpaired Student’s t test on a 
GraphPad software program (Prism 4.0). All of the statistical tests were 
2 sided. A P value of 0.05 was considered to be statistically significant.
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